CITED1 expression in liver development and hepatoblastoma

Neoplasia (United States)

Volumn 14, Issue 12, 2012, Pages 1153-1163

  Murphy, Andrew J ^a   de Caestecker, Christian ^a   Pierce, Janene ^a   Boyle, Scott C ^b   Ayers, Gregory D ^a   Zhao, Zhiguo ^a   Libes, Jaime M ^a   Correa, Hernan ^a   Walter, Teagan ^c   Huppert, Stacey S ^c   Perantoni, Alan O ^d   de Caestecker, Mark P ^a,c   Lovvorn, Harold N ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1, 4 DIHYDRO 2, 4, 6 TRIMETHYL 3, 5 PYRIDINEDICARBOXYLIC ACID DIETHYL ESTER; BETA CATENIN; HISTONE ACETYLTRANSFERASE PCAF; MESSENGER RNA; UNCLASSIFIED DRUG; WNT PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEPATOBLASTOMA; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER DEVELOPMENT; LIVER INJURY; LIVER REGENERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

EID: 84871586959     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12958     Document Type: Article

References (34)

1. Litten JB and Tomlinson GE (2008). Liver tumors in children. Oncologist 13, 812-820.
2. Malogolowkin MH, Katzenstein HM, Meyers RL, Krailo MD, Rowland JM, Haas J, and Finegold MJ (2011). Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group. J Clin Oncol 29, 3301-3306.
3. Scotting PJ, Walker DA, and Perilongo G (2005). Childhood solid tumours: a developmental disorder. Nat Rev Cancer 5, 481-488.
4. Ruck P and Xiao JC (2002). Stem-like cells in hepatoblastoma. Med Pediatr Oncol 39, 504-507.
5. Ruck P, Xiao JC, and Kaiserling E (1996). Small epithelial cells and the histogenesis of hepatoblastoma. Electron microscopic, immunoelectron microscopic, and immunohistochemical findings. Am J Pathol 148, 321-329.
6. Si-Tayeb K, Lemaigre FP, and Duncan SA (2010). Organogenesis and development of the liver. Dev Cell 18, 175-189.
7. Jeng YM, Wu MZ, Mao TL, Chang MH, and Hsu HC (2000). Somatic mutations of β-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 152, 45-51.
8. Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, and Buendia MA (2000). Activation of β-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 19, 498-504.
9. Boyle S, Shioda T, Perantoni AO, and de Caestecker M (2007). Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. Dev Dyn 236, 2321-2330.
10. Hendry C, Rumballe B, Moritz K, and Little MH (2011). Defining and redefining the nephron progenitor population. Pediatr Nephrol 26, 1395-1406.
11. Plisov S, Tsang M, Shi G, Boyle S, Yoshino K, Dunwoodie SL, Dawid IB, Shioda T, Perantoni AO, and de Caestecker MP (2005). Cited1 is a bifunctional transcriptional cofactor that regulates early nephronic patterning. J Am Soc Nephrol 16, 1632-1644.
12. Dressler GR (2009). Advances in early kidney specification, development and patterning. Development 136, 3863-3874.
13. Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, Friedman R, Klein U, and Tycko B (2002). Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160, 2181-2190.
14. Davidoff AM (2009). Wilms' tumor. Curr Opin Pediatr 21, 357-364.
15. Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VV, Grundy PE, Fearon ER, et al. (2004). CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 165, 1943-1953.
16. Huff V (2011). Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 11, 111-121.
17. Lovvorn HN, Westrup J, Opperman S, Boyle S, Shi G, Anderson J, Perlman EJ, Perantoni AO, Wills M, and de Caestecker M (2007). CITED1 expression in Wilms' tumor and embryonic kidney. Neoplasia 9, 589-600.
18. Murphy AJ, Pierce J, de Caestecker C, Taylor C, Anderson JR, Perantoni AO, de Caestecker MP, and Lovvorn H III (2011). SIX2 and CITED1, markers of nephronic progenitor self-renewal, remain active in primitive elements of Wilms' tumor. J Pediatr Surg 47, 1239-1249.
19. Lovvorn HN III, Boyle S, Shi G, Shyr Y, Wills ML, Perantoni AO, and de Caestecker M (2007). Wilms' tumorigenesis is altered by misexpression of the transcriptional co-activator, CITED1. J Pediatr Surg 42, 474-481.
20. Sado T, Fenner MH, Tan SS, Tam P, Shioda T, and Li E (2000). X inactivation in the mouse embryo deficient for Dnmt1: distinct effect of hypomethylation on imprinted and random X inactivation. Dev Biol 225, 294-303.
21. Beebe LE, Fornwald LW, Diwan BA, Anver MR, and Anderson LM (1995). Promotion of N -nitrosodiethylamine-initiated hepatocellular tumors and hepatoblastomas by 2,3,7,8-tetrachlorodibenzo-p-dioxin or Aroclor 1254 in C57BL/6, DBA/2, and B6D2F1 mice. Cancer Res 55, 4875-4880.
22. Wang X, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, and Grompe M (2003). The origin and liver repopulating capacity of murine oval cells. Proc Natl Acad Sci USA 100(suppl 1), 11881-11888.
23. Chen TT, Rakheja D, Hung JY, Hornsby PJ, Tabaczewski P, Malogolowkin M, Feusner J, Miskevich F, Schultz R, and Tomlinson GE (2009). Establishment and characterization of a cancer cell line derived from an aggressive childhood liver tumor. Pediatr Blood Cancer 53, 1040-1047.
24. Shi G, Boyle SC, Sparrow DB, Dunwoodie SL, Shioda T, and de Caestecker MP (2006). The transcriptional activity of CITED1 is regulated by phosphorylation in a cell cycle-dependent manner. J Biol Chem 281, 27426-27435.
25. Masuda N, Fukuoka M, Takada M, Kudoh S, and Kusunoki Y (1991). Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4). Chest 100, 429-438.
26. Holm S (1979). A simple sequentially rejective Bonferroni test procedure. Scand J Stat 6, 65-70.
27. Dunwoodie SL, Rodriguez TA, and Beddington RS (1998). Msg1 and Mrg1, founding members of a gene family, show distinct patterns of gene expression during mouse embryogenesis. Mech Dev 72, 27-40.
28. Armengol C, Cairo S, Fabre M, and Buendia MA (2011). Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. Int J Biochem Cell Biol 43, 265-270.
29. Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer CG, Albrecht S, Von Schweinitz D, and Pietsch T (2003). Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest 83, 429-434.
30. Qu X, Lam E, Doughman YQ, Chen Y, Chou YT, Lam M, Turakhia M, Dunwoodie SL, Watanabe M, Xu B, et al. (2007). Cited2, a coactivator of HNF4α;, is essential for liver development. EMBO J 26, 4445-4456.
31. Novitskaya T, Baserga M, and de Caestecker MP (2011). Organ-specific defects in insulin-like growth factor and insulin receptor signaling in late gestational asymmetric intrauterine growth restriction in Cited1 mutant mice. Endocrinology 152, 2503-2516.
32. Teo JL and Kahn M (2010). The Wnt signaling pathway in cellular proliferation and differentiation: a tale of two coactivators. Adv Drug Deliv Rev 62, 1149-1155.
33. Yahata T, de Caestecker MP, Lechleider RJ, Andriole S, Roberts AB, Isselbacher KJ, and Shioda T (2000). The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors. J Biol Chem 275, 8825-8834.
34. Koch A, Waha A, Hartmann W, Hrychyk A, Schuller U, Wharton KA Jr, Fuchs SY, von Schweinitz D, and Pietsch T (2005). Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 11, 4295-4304.